<DOC>
	<DOC>NCT00550017</DOC>
	<brief_summary>The purpose of this clinical research study is to study the safety of Epofolate (BMS-753493) in patients with advanced cancers (in Phase 1 portion) and to determine whether Epofolate (BMS-753493) can shrink or slow the growth of the cancer in patients with advanced ovarian, renal or breast cancer (in Phase 2 portion)</brief_summary>
	<brief_title>A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)</brief_title>
	<detailed_description />
	<criteria>Advanced cancer, excluding cancer in the blood Availability of 10 tumor tissue slides Known brain metastases Severe nerve damage Significant cardiovascular disease Inadequate blood counts Inadequate liver or kidney function Inadequate thyroid function or uncontrolled thyroid disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>